Innovation is the power fueling the development of the biopharmaceutical companies.  Henlius continues its momentum for a diversified innovation by enhancing internal innovation capacityies and reaching out to more strategic partners. Building upon the accumulated resources and technologies in the field of biologic medicines, Henlius has been establishing a forward-looking presence in innovative targets, bispecific antibodies as well as the antibody-drug conjugates (ADC). With anti-PD-1 product as core, Henlius has replenished a diversified and differentiated innovation pipeline covering the candidate targets including HER2, EGFR, PD-1/L1, c-MET, S1 Protein of SARS-CoV-2, LAG-3, TROP2, BRAF,etc. with the aim of addressing some of the most significant unmet needs.

 

Serplulimab injection (anti-PD-1 mAb) is the core innovative product independently researched and developed by Henlius. Combined with other products, it could be applied in the treatment of solid tumors for immuno-oncology therapy. In April 2021, its New Drug Application (NDA) for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that fail to respond to the standard therapy has been accepted by the National Medical Products Administration (NMPA) and granted priority review status. Serplulimab is potentially to be the first anti-PD-1 mAb indicated for MSI-H solid tumors in China. For this indication, patients are screened by specific MSI-H tumor markers, rather than by different tumor types, with a wide range of patient population. Henlius adopts the “Combo+Global” development strategy for serplulimab injection, focusing on indication differentiation and combination therapy, with a total of 10 clinical trials conducted worldwide.